Trials / Completed
CompletedNCT06258213
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Atom Therapeutics Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABP-745 | 0.5, 5 or 25 mg tablet |
| DRUG | Placebo | Placebo tablet |
Timeline
- Start date
- 2024-01-23
- Primary completion
- 2024-07-29
- Completion
- 2024-07-29
- First posted
- 2024-02-14
- Last updated
- 2025-08-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06258213. Inclusion in this directory is not an endorsement.